Percheron Therapeutics Future Growth
Future criteria checks 5/6
Percheron Therapeutics is forecast to grow earnings and revenue by 19.8% and 45.3% per annum respectively. EPS is expected to grow by 29% per annum. Return on equity is forecast to be -231.6% in 3 years.
Key information
19.8%
Earnings growth rate
29.0%
EPS growth rate
| Pharmaceuticals earnings growth | 21.5% |
| Revenue growth rate | 45.3% |
| Future return on equity | -231.6% |
| Analyst coverage | Low |
| Last updated | 07 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2027 | 11 | 6 | -38 | -38 | 2 |
| 6/30/2026 | 1 | -20 | -16 | -16 | 3 |
| 6/30/2025 | 1 | -40 | -17 | -17 | 2 |
| 6/30/2024 | 3 | -12 | -10 | -10 | N/A |
| 3/31/2024 | 3 | -11 | -10 | -10 | N/A |
| 12/31/2023 | 2 | -11 | -10 | -10 | N/A |
| 9/30/2023 | 2 | -11 | -9 | -9 | N/A |
| 6/30/2023 | 2 | -11 | -8 | -8 | N/A |
| 3/31/2023 | 2 | -10 | -7 | -7 | N/A |
| 12/31/2022 | 2 | -8 | -7 | -7 | N/A |
| 9/30/2022 | 2 | -7 | -7 | -7 | N/A |
| 6/30/2022 | 2 | -6 | -8 | -8 | N/A |
| 3/31/2022 | 1 | -7 | -8 | -8 | N/A |
| 12/31/2021 | 1 | -9 | -8 | -8 | N/A |
| 9/30/2021 | 1 | -9 | -7 | -7 | N/A |
| 6/30/2021 | 1 | -8 | -6 | -6 | N/A |
| 3/31/2021 | 1 | -6 | -5 | -5 | N/A |
| 12/31/2020 | 1 | -4 | -4 | -4 | N/A |
| 9/30/2020 | 1 | -5 | -4 | -4 | N/A |
| 6/30/2020 | 1 | -6 | -4 | -4 | N/A |
| 3/31/2020 | 1 | -6 | -3 | -3 | N/A |
| 12/31/2019 | 1 | -6 | -3 | -3 | N/A |
| 9/30/2019 | 1 | -4 | -3 | -3 | N/A |
| 6/30/2019 | 1 | -3 | -3 | -3 | N/A |
| 3/31/2019 | 0 | -3 | -3 | -3 | N/A |
| 12/31/2018 | 0 | -3 | -3 | -3 | N/A |
| 9/30/2018 | 0 | -3 | -3 | -3 | N/A |
| 6/30/2018 | 0 | -2 | -2 | -2 | N/A |
| 3/31/2018 | 0 | -2 | N/A | -2 | N/A |
| 12/31/2017 | 0 | -2 | N/A | -3 | N/A |
| 9/30/2017 | 1 | -3 | N/A | -3 | N/A |
| 6/30/2017 | 1 | -3 | N/A | -3 | N/A |
| 3/31/2017 | 1 | -2 | N/A | -2 | N/A |
| 12/31/2016 | 1 | -2 | N/A | -2 | N/A |
| 9/30/2016 | 2 | -2 | N/A | -2 | N/A |
| 6/30/2016 | 2 | -3 | N/A | -2 | N/A |
| 3/31/2016 | 3 | -1 | N/A | -1 | N/A |
| 12/31/2015 | 4 | 1 | N/A | 0 | N/A |
| 9/30/2015 | 5 | 1 | N/A | 1 | N/A |
| 6/30/2015 | 5 | 1 | N/A | 1 | N/A |
| 3/31/2015 | 3 | -1 | N/A | -1 | N/A |
| 12/31/2014 | 1 | -3 | N/A | -3 | N/A |
| 9/30/2014 | 1 | -3 | N/A | -3 | N/A |
| 6/30/2014 | 1 | -3 | N/A | -3 | N/A |
| 3/31/2014 | 1 | -3 | N/A | -2 | N/A |
| 12/31/2013 | 1 | -3 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AWY0 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: AWY0 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AWY0 is expected to become profitable in the next 3 years.
Revenue vs Market: AWY0's revenue (45.3% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: AWY0's revenue (45.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AWY0 is forecast to be unprofitable in 3 years.